NCX 1728
Alternative Names: NCX-1728Latest Information Update: 27 Sep 2024
At a glance
- Originator NicOx
- Class Antiglaucomas; Eye disorder therapies; Nitro compounds
- Mechanism of Action Nitric oxide donors; Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Glaucoma